Φορτώνει......
Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment
Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is a novel oral multikinase inhibitor that blocks the activity of several protein kinases. However, few guidelines exist for novel biomarkers to select patients who will likely benefit from regorafenib treatment. Metastatic colore...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Ther Adv Med Oncol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
SAGE Publications
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7649869/ https://ncbi.nlm.nih.gov/pubmed/33224274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920965842 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|